Signing up for CABLIVI Patient Solutions provides guidance and support throughout your journey with CABLIVI and aTTP/iTTP*
A dedicated team will work together seamlessly to help manage your acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) care.
Meet your CABLIVI Patient Solutions team
YOUR CASE MANAGER
Your main point of contact on the team,
helping with financial assistance for
eligible patients and specialty
pharmacy services
YOUR CLINICAL EDUCATOR
Your educator about all things CABLIVI,
from injection training to product
knowledge
YOUR THERAPEUTIC EDUCATION MANAGER (TEM)
Your ally for ongoing support on
understanding and living with aTTP/
iTTP and advocating for yourself
If you are prescribed CABLIVI and want to apply for available patient assistance programs, you and your doctor can fill out the CABLIVI Patient Solutions enrollment form
Sanofi reserves the right to modify or terminate these programs at any time without notice.
Financial assistance for eligible patients
Case Managers (your main point of contact) can help you understand the financial support available to you based on your insurance status:
-
Support is available to cover the cost of CABLIVI co-pay or co-insurance for qualified, commercially insured patients up to the program maximum†
-
CABLIVI will be provided at no cost to eligible, underinsured, or uninsured patients‡
Specialty pharmacy services
Case Managers can assist you with managing shipment of your CABLIVI therapy to your home if your doctor prescribes CABLIVI through a specialty pharmacy:
-
Dispensing pharmacists are available 24 hours a day, 7 days a week
-
If your doctor decides you need a refill, the specialty pharmacy will call you to arrange your delivery of CABLIVI according to your prescription
Supplemental injection training
Clinical Educators§ provide the following at no extra cost to you:
-
Additional one-on-one training about how to administer CABLIVI by yourself
-
Answers to your questions about CABLIVI and aTTP/iTTP
-
Support to help you stay on your treatment schedule
Training is provided in person or virtually 7 days a week to meet your scheduling needs.
Ongoing education
Therapeutic Education Managers§ (TEMs) are experienced in rare blood disorders and committed to educating people living with aTTP/iTTP, their families, and care partners about topics such as:
-
Disease education
-
How you can help manage your condition
-
Having empowering conversations with your care team
Even if you are not prescribed CABLIVI, TEMs are available to provide education and answer questions
CABLIVI Patient Solutions is available Monday through Friday, 8:00 AM to 8:00 PM ET, at 1-855-724-7222
CABLIVI Patient Solutions
Learn more about the support offered through CABLIVI Patient Solutions.
CABLIVI Patient Solutions Enrollment Form
Enroll in CABLIVI Patient Solutions with the help of your healthcare provider to access financial assistance, specialty pharmacy services, injection training, and more.
You can stay informed about all things aTTP/iTTP and CABLIVI
CABLIVI, in combination with PEX and immunosuppression, can help you take on aTTP/iTTP with confidence
*aTTP is also known as iTTP. You and your healthcare team can use either term.
†Not valid for CABLIVI prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, Tricare, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. Savings may vary depending on the patient’s out-of-pocket costs. Upon registration, the patient will receive all program details.
‡Approval is not guaranteed. Sanofi reserves the right to modify or discontinue the programs at any time. Terms and conditions apply.
§Clinical Educators and Therapeutic Education Managers are paid to provide educational services by Sanofi and do not provide medical advice. Patients should always consult their doctor with any questions or concerns regarding their medical condition or healthcare needs.
aTTP/iTTP=acquired/immune-mediated thrombotic thrombocytopenic purpura.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.